Historical Valuation
Teladoc Health Inc (TDOC) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.49 is considered Undervalued compared with the five-year average of -28.53. The fair price of Teladoc Health Inc (TDOC) is between 1545.40 to 1547.66 according to relative valuation methord. Compared to the current price of 7.46 USD , Teladoc Health Inc is Undervalued By 99.52%.
Relative Value
Fair Zone
1545.40-1547.66
Current Price：7.46
99.52%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Teladoc Health Inc (TDOC) has a current Price-to-Book (P/B) ratio of 0.90. Compared to its 3-year average P/B ratio of 1.24 , the current P/B ratio is approximately -27.83% higher. Relative to its 5-year average P/B ratio of 1.22, the current P/B ratio is about -26.51% higher. Teladoc Health Inc (TDOC) has a Forward Free Cash Flow (FCF) yield of approximately 22.39%. Compared to its 3-year average FCF yield of 14.85%, the current FCF yield is approximately 50.72% lower. Relative to its 5-year average FCF yield of 9.47% , the current FCF yield is about 136.42% lower.
P/B
Median3y
1.24
Median5y
1.22
FCF Yield
Median3y
14.85
Median5y
9.47
Competitors Valuation Multiple
AI Analysis for TDOC
The average P/S ratio for TDOC competitors is 442.14, providing a benchmark for relative valuation. Teladoc Health Inc Corp (TDOC.N) exhibits a P/S ratio of 0.49, which is -99.89% above the industry average. Given its robust revenue growth of -2.20%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for TDOC
1Y
3Y
5Y
Market capitalization of TDOC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of TDOC in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is TDOC currently overvalued or undervalued?
Teladoc Health Inc (TDOC) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.49 is considered Undervalued compared with the five-year average of -28.53. The fair price of Teladoc Health Inc (TDOC) is between 1545.40 to 1547.66 according to relative valuation methord. Compared to the current price of 7.46 USD , Teladoc Health Inc is Undervalued By 99.52% .
What is Teladoc Health Inc (TDOC) fair value?
TDOC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Teladoc Health Inc (TDOC) is between 1545.40 to 1547.66 according to relative valuation methord.
How does TDOC's valuation metrics compare to the industry average?
The average P/S ratio for TDOC's competitors is 442.14, providing a benchmark for relative valuation. Teladoc Health Inc Corp (TDOC) exhibits a P/S ratio of 0.49, which is -99.89% above the industry average. Given its robust revenue growth of -2.20%, this premium appears unsustainable.
What is the current P/B ratio for Teladoc Health Inc (TDOC) as of Jan 10 2026?
As of Jan 10 2026, Teladoc Health Inc (TDOC) has a P/B ratio of 0.90. This indicates that the market values TDOC at 0.90 times its book value.
What is the current FCF Yield for Teladoc Health Inc (TDOC) as of Jan 10 2026?
As of Jan 10 2026, Teladoc Health Inc (TDOC) has a FCF Yield of 22.39%. This means that for every dollar of Teladoc Health Inc’s market capitalization, the company generates 22.39 cents in free cash flow.
What is the current Forward P/E ratio for Teladoc Health Inc (TDOC) as of Jan 10 2026?
As of Jan 10 2026, Teladoc Health Inc (TDOC) has a Forward P/E ratio of -7.68. This means the market is willing to pay $-7.68 for every dollar of Teladoc Health Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Teladoc Health Inc (TDOC) as of Jan 10 2026?
As of Jan 10 2026, Teladoc Health Inc (TDOC) has a Forward P/S ratio of 0.49. This means the market is valuing TDOC at $0.49 for every dollar of expected revenue over the next 12 months.